A Study of the Structure and Function of the Retina in Adult Patients With Refractory Complex Partial Seizures Treated With Vigabatrin (Sabril®)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Lundbeck LLC
ClinicalTrials.gov Identifier:
NCT01278173
First received: January 14, 2011
Last updated: April 28, 2016
Last verified: April 2016
Results First Received: April 28, 2016  
Study Type: Interventional
Study Design: Endpoint Classification: Safety Study;   Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Supportive Care
Condition: Adult Refractory Complex Partial Seizures
Intervention: Drug: Sabril

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Sabril Vigabatrin, 500 mg tablets, orally. Physicians will dose their patients according to guidance provided in the product label.

Participant Flow:   Overall Study
    Sabril  
STARTED     65  
COMPLETED     38  
NOT COMPLETED     27  
Lack of Efficacy                 13  
Adverse Event                 8  
Administrative or other reason                 4  
Protocol Violation                 1  
Withdrawal by Subject                 1  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
All patients who took at least one dose of IMP.

Reporting Groups
  Description
Sabril Vigabatrin, 500 mg tablets, orally. Physicians will dose their patients according to guidance provided in the product label.

Baseline Measures
    Sabril  
Number of Participants  
[units: participants]
  65  
Age  
[units: years]
Mean (Standard Deviation)
  39.8  (12.3)  
Gender  
[units: participants]
 
Female     28  
Male     37  
Race (NIH/OMB)  
[units: participants]
 
American Indian or Alaska Native     0  
Asian     2  
Native Hawaiian or Other Pacific Islander     0  
Black or African American     5  
White     58  
More than one race     0  
Unknown or Not Reported     0  
Region of Enrollment  
[units: participants]
 
United States     65  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Mean Change From Reference Value in Field Width as Measured by 30-2 SITA Fast in Field Sensitivity (Mean Deviation - MD in dB)   [ Time Frame: Baseline (Month 0), Month 3, Month 6, Month 9, Month 12 ]

2.  Primary:   Change From Reference Value in Average RNFL (Retinal Nerve Fiber Layer) Thickness (µm) as Measured by SD-OCT (Spectral Domain-Optical Coherence Tomography)   [ Time Frame: Baseline (Month 0), Month 3, Month 6, Month 9, Month 12 ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: H
Organization: Lundbeck
e-mail: LundbeckClinicalTrials@Lundbeck.com



Responsible Party: Lundbeck LLC
ClinicalTrials.gov Identifier: NCT01278173     History of Changes
Other Study ID Numbers: 13098A
Study First Received: January 14, 2011
Results First Received: April 28, 2016
Last Updated: April 28, 2016
Health Authority: United States: Food and Drug Administration